Long-Awaited Cost Analysis of Early Palliative Care Intervention in Patients with Metastatic Lung Cancer

VBCC - November 2014, Vol 5, No 9 - Palliative Care
Kate O’Rourke

Boston, MA—A long-awaited cost analysis of a randomized trial comparing early palliative care with standard care in patients with metastatic non–small-cell lung cancer (NSCLC) did not produce results that reached statistical significance, but the findings were positive, the researchers said, given that early palliative care has been shown to improve survival and other outcomes.

“Early palliative care has been shown to improve quality of life, mood, and end-of-life care in patients with metastatic NSCLC,” said Joseph A. Greer, PhD, a clinical psychologist at Massachusetts General Hospital, Boston, who presented the study at the 2014 Palliative Care in Oncology Symposium.

“The marginally significant findings show that early palliative care was associated with a lower average total cost per day of $117 compared with standard care,” said Dr Greer. “In the final month of life, costs were greater for hospice care, but less for chemotherapy in the early palliative care group compared with standard care.”

According to an estimate from a 2011 study, the average cumulative total healthcare cost for metastatic lung cancer is $125,849 (Vera-Llonch M, et al. BMC Health Serv Res. 2011; 11:305). Palliative care may be one method of reducing these healthcare costs. Inpatient palliative care consultations have been associated with significant savings for hospital costs (May P, et al. J Palliat Med. 2014;17:1054-1063), yet little is known about the impact of outpatient early palliative care on the overall costs of care.

Clinical Outcomes
A landmark randomized controlled trial conducted at Massachusetts General Hospital demonstrated that early palliative care improved survival, quality of life, and depression in patients with metastatic NSCLC (Temel JS, et al. N Engl J Med. 2010;363:733-742). The study randomized 151 patients with newly diagnosed metastatic NSCLC to receive either standard cancer care alone or early palliative care integrated with standard care.

Patients in the palliative care arm met with palliative care clinicians monthly, whereas patients in the standard oncology arm met with palliative care clinicians only when the patient or family requested it. Although fewer patients in the early palliative care group than in the standard care group received aggressive end-of-life care (33% vs 54%, respectively; P = .05), the median survival was longer among patients receiving early palliative care (11.6 vs 8.9 months, respectively; P = .02).

A New Cost Analysis
At the meeting, Dr Greer presented the results of a new, secondary analysis of the original study, which calculated the cost of care throughout the original study and at the end of life in terms of hospitalizations and emergency department visits, outpatient clinic visits, chemotherapy administration, and hospice services.

Although many of the costs showed a trend toward a cost-savings for the palliative care arm, the results did not reach statistical significance (Table 1 and Table 2).

Table 1

Table 2

“Although this secondary analysis lacked statistical power, the delivery of early palliative care for patients with metastatic NSCLC does not appear to increase health care expenses over the course of disease or at the end of life.”

Dr Greer said that future studies of early palliative care models need to include sufficiently powered cost analyses that assess relevant inpatient, outpatient, and homecare services.

Eduardo Bruera, MD, Professor and Chair, Department of Palliative Care and Rehabilitation Medicine, M.D. Anderson Cancer Center, Houston, discussed the study at the symposium. Dr Bruera said that the research was important, because it showed that the costs of early palliative care were not higher than standard care, but that the expenses had a different distribution.

Related Items
Family Patient-Related Factors Main Barriers to End-of-Life Discussions
Meg Barbor, MPH
VBCC - December 2015, Vol 6, No 11 published on December 16, 2015 in Palliative Care
Teamwork Improves End-of-Life Care, Saves Money
Phoebe Starr
VBCC - December 2015, Vol 6, No 11 published on December 16, 2015 in Palliative Care
Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL
Phoebe Starr
VBCC - June 2015, Vol 6, No 5 published on June 22, 2015 in Palliative Care
Early Initiation of Palliative Care Improves Survival in Patients with Advanced Cancer
Laura Morgan
VBCC - June 2015, Vol 6, No 5 published on June 22, 2015 in Palliative Care
Main Barriers to Quality Lung Cancer Care Relate to Navigating the Healthcare System
Kate O’Rourke
VBCC - February 2015, Vol 6, No 1 published on February 19, 2015 in Quality Care
New Policy Mandates Poised to Change Discussions About Death and Dying
Kate O’Rourke
VBCC - December 2014, Vol 5, No 10 published on December 24, 2014 in Palliative Care
Supportive Care Is Palliative
Kate O’Rourke
VBCC - December 2014, Vol 5, No 10 published on December 22, 2014 in Palliative Care
Timing of Palliative Care Delivery in Patients with Cancer Impacts Quality and Cost Outcomes
Kate O’Rourke
VBCC - November 2014, Vol 5, No 9 published on November 24, 2014 in Palliative Care
Study Quantifies the Cost-Savings of Do Not Resuscitate Orders
Kate O’Rourke
VBCC - November 2014, Vol 5, No 9 published on November 24, 2014 in Palliative Care
Inappropriate Use of Adjuvant Chemotherapy Common in Patients with Lung or Colon Cancer
Kate O’Rourke
VBCC - November 2014, Vol 5, No 9 published on November 21, 2014 in ASCO Quality Care Symposium
Last modified: November 24, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology